All In Biotech

Drug Trial Radar · NCT06132828

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Nov 27, 2023

Primary completion

Jul 30, 2027

Study completion Sep 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors

Conditions

  • Solid Tumor

Interventions

  • DR30206Drug

    Subjects receive DR30206 intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PartA: Incidence of dose limiting toxicities (DLTs)Time frame: 21 days following first dose
  2. PartA: Maximum tolerated dose (MTD)Time frame: 21 days following first dose
  3. PartA: Recommend dose of expansion(RDE)Time frame: 21 days following first dose
  4. PartA+B: Adverse evens (AEs)Time frame: Up to 90 days after last dose
  5. PartA+B: Serious adverse evens (SAEs)Time frame: Up to 90 days after last dose
  6. PartB: Objective response rate (ORR)Time frame: Up to approximately 12 months
  7. PartB: Recommended phase 2 dose (RP2D)Time frame: 21 days following first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.